Tumor angiogenesis depends on a balance of activators and inhibitors of angiogenesis (angiogenic switch). [1] [2] [3] Microenvironmental determinants of angiogenesis include (1) pro-inflammatory cytokines, as tumor necrosis factor alpha (TNF-a), which can act either as an activator 4 or inhibitor 5 of angiogenesis; and (2) metalloproteinases 6 that remodel the extracellular matrix (ECM). ECM remodelling is often associated with release of ECMresident growth factors, as fibroblast growth factor-2 (FGF-2). 7, 8 TNF-a and FGF-2 set the stage for angiogenesis by modulating the expression of growth factors. [7] [8] [9] Vascular endothelial growth factor (VEGF) has been identified as one of the most potent activators of tumor angiogenesis. 10, 11 VEGF is a highly specific mitogen for vascular endothelial cells, regulating several steps of the angiogenic process, including endothelial cell migration and proliferation. [10] [11] [12] [13] The VEGF gene consists of eight exons that are expressed in different combinations by alternative splicing mechanisms regulated by a single promoter. 14, 15 In the mouse, VEGF gene splicing results in at least three VEGF isoforms: VEGF 120 , VEGF 164 , and VEGF 188 (the corresponding human isoforms are one residue longer). 15 VEGF isoforms are glycosylated homodimers [14] [15] [16] [17] and inherit both mitogenic and permeable properties. 18, 19 Recent investigations have focused on the control of VEGF isoform expression as a means of controlling angiogenesis during tumor development. 20 Analysis of the human 14 and mice 15 VEGF gene promoter region revealed a cluster of potential Sp1 factor binding sites. Likewise the promoter of the TNF-a gene is also under the control of Sp1 factors. 21 Transcription factor Sp1 binds to the GC box, which can be found in the promoter region of a variety of constitutive and inducible mammalian genes. [22] [23] [24] [25] [26] Although Sp1 binding has been shown to activate gene transcription, 25 for some genes, Sp1 acts as a repressor. 27, 28 The promoter motifs or cellular determinants of such divergent effects of Sp1 binding are not fully understood. Ryuto 0 . The underlined sequences represent the consensus-binding site for Sp1 transcription factor (GenBank accession number U41383). Mutations in Sp1 decoy ODNs are indicated in bold. All animals survived and were killed after seven cycles of treatment by intraperitoneal injections of pentobarbital (200 mg/kg body weight). Tumors were collected, fixed, and embedded according to routine histopathology protocols. In total, 6 -mm-thick sections through the tumors were then either stained for hematoxilin-eosin (HE) or immunohistochemically stained with a monoclonal antibody to CD-34 (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). HE-stained sections (n¼8 for SP1 decoy ODN-treated tumors and control tumors) were then analyzed for the fraction of necrotic areas and microvessel density was measured in the CD-34-stained sections (n¼8 for SP1 decoy ODN-treated tumors and control tumors) using a Leica Q Win (Leica, Bensheim Germany) image analysis system. The animal ethics committee of the Medical School of the University of São Paulo approved all experimental protocols. Semiquantitative analysis of microvessel density was performed as suggested by an International Consensus report. 31 As revealed by CD-34 immunostaining, a dense, highly heterogeneous vessel network became obvious in tumor sections treated with mutated ODNs (Figure 1a ). In contrast, Sp1 decoy ODN-treated tumor sections were characterized by sparsely distributed rather large vessels ( Figure 1b ). Our semiquantitative analysis revealed that microvessel density in melanoma tumors treated with Sp1 decoy ODNs was indeed significantly decreased as compared with control tumors (4.872.2 versus 13.778.2 vessels/mm 2 ; P¼0.012; Figure  1c ). A significant decrease in microvessel densities was not only found in bilaterally injected animals but also in unilaterally injected animals (5.671.0 versus 16.973.6 vessels/mm 2 ; P¼0.01; data not shown). There was also a significant difference between Sp1 decoy ODN-treated tumors and control tumors with regard to the relative tumor area covered by blood vessels (relative vascular Figure 1d ).
The histological analysis of HE-stained sections revealed that Sp1 decoy ODNs promoted a dramatic increase of necrotic areas within melanoma tumors ( Figure 2) . While in the controls only small and restricted necrotic areas became obvious (Figure 2a ), Sp1 decoy ODN-treated tumors displayed large and diffuse necrotic areas with an intense inflammatory infiltrate (Figure 2b,  c) . The relative necrotic area in melanoma tumors treated with Sp1 decoy ODNs was around 2.5-fold higher than in control tumors (5.4676.42 versus 2.0372.57%; P¼0.041; data not shown).
As illustrated in Figure 2c , signs of apoptotic cell death, as chromatin condensation, nuclear fragmentation, and the occurrence of apoptotic bodies were occasionally found among necrotic cells in the tumors treated with Sp1 decoy ODNs. The presence of a restricted number of apoptotic nuclei in these tumors (n¼4) was further confirmed by TUNEL labeling (Figure  2d , e). In contrast, no TUNEL-positive nuclei at all could be detected in tumors treated with mutated Sp1 decoy ODNs (n¼4; data not shown).
As a next step, we analyzed by RT-PCR (n¼8 for SP1 decoy ODN-treated tumors and control tumors) whether the expression levels of the differentially spliced VEGF isoforms and of TNF-a were affected by Sp1 decoy ODNs. All three differentially spliced VEGF isoforms could be detected in mutated Sp1 decoy ODNs-treated tumors ( Figure 3, lane 2) . A decrease in the levels of VEGF 188 amplification product and a complete inhibition of VEGF 164 expression was persistently observed in Sp1 decoy ODN-treated melanomas, whereas the expression of VEGF 120 appeared almost unchanged (Figure 3, lane  3) . In addition, we observed a moderate consistent decrease in the expression levels of TNF-a (Figure 3 , lane 5).
The present results provide further evidence that synthetic double-stranded ODNs with high affinity for a target transcription factor can be introduced into cells as decoy cis-element to bind the factors and alter gene expression. Our findings indicate that uptake of Sp1 decoy ODNs designed to neutralize the transcription factor Sp1 action was sufficient to alter TNF-a and VEGF isoform expression in mouse melanoma tumors. The morphometrically measured significant reduction of microvessel density following treatment with Sp1 decoy ODNs provides strong evidence that our treatment indeed affects neovascularization in melanoma tumors. We have extended the in vitro findings of Ishibashi et al, 30 who have provided evidence that treatment of human cell lines with Sp1 decoy ODNs altered TNF-a expression. Using a similar approach in vivo, we showed here that besides TNF-a expression, VEGF gene expression was also modified, and we cannot exclude that the expression patterns of other genes potentially regulated by Sp1, such as the kinase domain receptor, 32 and FGF-4 gene 33 were also affected. Moreover, our strategy was effective to inhibit angiogenesis within the melanoma tumor microenvironment. These findings make it highly probable that the observed increase in necrosis and 30 The selective inhibition in the expression of the VEGF 164 and VEGF 188 isoforms and the somewhat surprising persistent expression of the VEGF 120 isoform suggest that the Sp1 decoy ODNs may not be acting directly on the VEGF promoter by controlling VEGF gene transcription, but rather by affecting VEGF splicing mechanisms. A very similar finding was recently described by Carè et al, 34 who studied the effect of the transcription factor HOXB7 on VEGF isoform expression in human melanoma cells. Interestingly, the authors showed that the blockage of HOXB7 expression by antisense nucleotides decreased the expression of both VEGF 165 and VEGF 189 isoforms, whereas the expression of VEGF 121 remained substantially unchanged. Moreover, the same group showed that the expression of the HOXB7 gene is controlled by Sp1 transcription factors. 35 Alternatively, the different cell types present within the tumor microenvironment may display different mechanisms for controlling gene expression. Subtle differences in the composition of the transcriptional control machinery, its repressors and activators, may account for the differences observed regarding the sensitivity to Sp1 decoy ODNs. Regardless of the precise mechanisms, the net decrease in TNF-a and VEGF isoform expression support the antiangiogenic effect of Sp1 decoy ODNs.
Presently, we can only speculate about the basic mechanisms by which Sp1 decoy ODNs might affect VEGF splicing and subsequently angiogenesis in our mouse model. A better understanding of the mechanisms of VEGF alternative splicing and the biological functions of its distinct isoforms appears crucial for the interpretation of our findings. However, as yet the exact mechanisms of VEGF splicing under normal conditions and in the context of cancer remain poorly understood. 20, 36, 37 Houck et al 37, 38 have demonstrated several different molecular VEGF species, which can be generated as a result of alternative splicing of VEGF RNA. The information encoded by this alternative splicing determines whether VEGF will be soluble or incorporated into a biological reservoir or undergo proteolysis. Grunstein et al 20 have shown in VEGF-deficient embryonic fibroblasts that VEGF 164 is fully competent to induce both external vessel capture and internal vascular expansion, whereas VEGF 120 is just partially efficient in tumorassociated angiogenesis, and VEGF 188 completely failed to rescue tumor expansion. Interestingly, the expression of VEGF 164 was completely abolished, the expression of VEGF 188 decreased substantially, whereas the expression of VEGF 120 was only little affected by our treatment. Some authors have postulated a major role of VEGF 121 for angiogenesis in human melanoma tumors, 39, 40 whereas VEGF 189 has been shown to be nontumorigenic. 36 Since VEGF 120 isoform expression was only little affected by our treatment with Sp1 decoy ODNs, it is tempting to speculate that in our mouse model VEGF 164 might play a pivotal role in angiogenesis. Consistent with this view are the results of Yu et al, 36 who transfected a human melanoma cell line (WM1341B) with either VEGF isoform and analyzed in detail the microvascular array present. The dense microvessel pattern observed in our control group was similar to that displayed by the VEGF 165 -positive tumors, whereas the pattern that we observed in melanoma tumors treated with Sp1 decoy ODNs resembled the pattern observed in grafts from cells transfected with VEGF 121 (poorly vascularized and necrotic). Stalmans et al 41 studied the vascular patterning in retinas of transgenic mice selectively expressing each one of the three VEGF isoforms. They described an impaired vascular outgrowth, similar as illustrated in our Figure 1b , in mice selectively expressing the VEGF 120 isoform, whereas mice selectively expressing the VEGF 164 isoform had normal retinal angiogenesis.
Previous studies 30, [42] [43] [44] [45] have demonstrated the potential utility of the decoy strategy for clinical application. Hata et al 32 showed that Sp1 decoy ODNs reduced expression of kinase domain receptor (KDR), a tyrosine kinase receptor for VEGF and an important mediator of endothelial growth and vascular development. Recently, Borgatti et al 46 have demonstrated the use of PNAs (peptide nucleic acids) and DNA-PNAs chimeras as decoy reagents able to inhibit molecular interactions between Sp1 and DNA. With regard to a possible cytotoxicity of Sp1 decoy ODNs, the results reported here in conjunction with recent more systematic studies on the cytotoxity of Sp-1 decoy ODNs in monkeys 42 indicate that treatment with Sp1 decoy ODNs might indeed provide a potential new clinical strategy to Antiangiogenic effect of Sp1 decoy oligodeoxynucleotides EM Novak et al regulate gene expression. However, in most studies so far, ODNs were delivered locally. Under these conditions not all tumor cells are exposed to the ODNs. This sole fact hampers the systematic analysis of treatment efficacy, as measured by survival. Therefore, future studies are necessary in order to perfect the ODN delivery strategy and to allow a realistic assessment of its therapeutic potential.
In summary, our results provide evidence that Sp1-decoy ODNs may inhibit angiogenesis in melanoma tumors by affecting the gene expression of TNF-a and VEGF, two key players in angiogenesis. Although the precise mechanisms of VEGF isoform expression/splicing remain unclear, these findings indicate that Sp1 decoy ODNs may represent a potential antiangiogenic therapeutic approach for the treatment of melanoma tumors.
